[go: up one dir, main page]

MX2019012884A - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX2019012884A
MX2019012884A MX2019012884A MX2019012884A MX2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A
Authority
MX
Mexico
Prior art keywords
combination
proliferative disease
treatment
subject
present
Prior art date
Application number
MX2019012884A
Other languages
English (en)
Other versions
MX393855B (es
Inventor
Cooke Vesselina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62218018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019012884(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019012884A publication Critical patent/MX2019012884A/es
Publication of MX393855B publication Critical patent/MX393855B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende (a) un inhibidor de Raf conforme lo definido en la presente, o una sal farmacéuticamente aceptable del mismo y (b) un inhibidor de MEK, particularmente trametinib, particularmente para usarse en el tratamiento de una enfermedad proliferativa. La presente invención además se refiere a usos de esta combinación para la preparación de un medicamento para el tratamiento de una enfermedad proliferativa; a métodos de tratamiento de una enfermedad proliferativa en un sujeto que lo necesite que comprenden administrar a dicho sujeto una cantidad conjuntamente terapéuticamente efectiva de dicha combinación; al uso de tal combinación para el tratamiento de una enfermedad proliferativa; a composiciones farmacéuticas que comprenden tal combinación y a envases comerciales para las mismas.
MX2019012884A 2017-05-02 2018-04-30 Terapia de combinación que comprende un inhibidor de raf y trametinib MX393855B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500108P 2017-05-02 2017-05-02
US201862656423P 2018-04-12 2018-04-12
PCT/IB2018/052989 WO2018203219A1 (en) 2017-05-02 2018-04-30 Combination therapy

Publications (2)

Publication Number Publication Date
MX2019012884A true MX2019012884A (es) 2020-01-14
MX393855B MX393855B (es) 2025-03-21

Family

ID=62218018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012884A MX393855B (es) 2017-05-02 2018-04-30 Terapia de combinación que comprende un inhibidor de raf y trametinib

Country Status (17)

Country Link
US (2) US11266653B2 (es)
EP (2) EP3618875B1 (es)
JP (3) JP7309614B2 (es)
KR (2) KR20240032157A (es)
CN (1) CN110494166B (es)
AU (1) AU2018262891B2 (es)
CA (1) CA3057969A1 (es)
CL (1) CL2019003091A1 (es)
DK (1) DK3618875T3 (es)
ES (1) ES2952265T3 (es)
FI (1) FI3618875T3 (es)
IL (2) IL270224B1 (es)
MX (1) MX393855B (es)
PL (1) PL3618875T3 (es)
PT (1) PT3618875T (es)
TW (1) TWI798218B (es)
WO (1) WO2018203219A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
KR20240032157A (ko) 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
CA3072345A1 (en) * 2017-08-11 2019-02-14 Curematch, Inc. Drug combinations for targeting multiple mutations in cancer
JP2022514056A (ja) * 2018-12-20 2022-02-09 ノバルティス アーゲー 癌の治療に使用するためのＲａｆ阻害剤及びＣＤＫ４／６阻害剤による組み合わせ療法
CN113795490A (zh) 2019-05-13 2021-12-14 诺华股份有限公司 N-(3-(2-(2-羟基乙氧基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-2(三氟甲基)异烟酰胺的新结晶形式作为Raf抑制剂治疗癌症
EP4106756A1 (en) * 2020-02-18 2022-12-28 Novartis AG Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
CN114207437B (zh) * 2020-02-27 2024-05-28 国立大学法人北海道大学 筛选抗癌剂的方法和用于治疗胰腺癌的激酶抑制剂的组合药物
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
EP4149472A1 (en) * 2020-05-12 2023-03-22 Novartis AG Therapeutic combinations comprising a craf inhibitor
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
TW202227088A (zh) * 2020-08-31 2022-07-16 瑞士商諾華公司 組合療法
US20250108051A1 (en) * 2022-01-27 2025-04-03 Tohoku University Therapeutic agent for cancer
EP4486920A2 (en) 2022-03-02 2025-01-08 Novartis AG Precision therapy for the treatment of cancer
TW202432544A (zh) 2022-09-07 2024-08-16 美商亞文納營運公司 快速加速纖維肉瘤降解化合物及相關使用方法
CN117919234A (zh) * 2022-10-25 2024-04-26 上海润石医药科技有限公司 一种萘酰胺化合物治疗耐药性肿瘤的用途
CN117919235A (zh) * 2022-10-25 2024-04-26 上海润石医药科技有限公司 一种萘酰胺化合物治疗kras突变相关疾病的用途
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
DE3029376A1 (de) 1980-07-31 1982-03-18 Nepera Chemical Co. Inc., Harriman, N.Y. Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
JP2722586B2 (ja) 1989-01-13 1998-03-04 大正製薬株式会社 インドリルイミダゾール誘導体
JP2808460B2 (ja) 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2001500482A (ja) 1996-08-27 2001-01-16 ノバルティス アクチェンゲゼルシャフト 除草性ｓ置換１，２，４，６―チアトリアジン類
JP4713698B2 (ja) 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6465493B1 (en) 1999-04-09 2002-10-15 Smithkline Beecham Corporation Triarylimidazoles
HUP0202708A3 (en) 1999-04-15 2004-12-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
AU7031500A (en) 1999-09-23 2001-04-24 Astrazeneca Ab Therapeutic quinazoline compounds
AU1529901A (en) 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
EP1251849A1 (en) 2000-01-18 2002-10-30 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CA2397686A1 (en) 2000-01-18 2001-07-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
ATE266022T1 (de) 2000-03-06 2004-05-15 Smithkline Beecham Plc Imidazol derivate als raf kinase inhibitoren
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
WO2001074811A2 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100850728B1 (ko) 2000-06-12 2008-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-디하이드로피리딘 화합물, 그의 제조 방법 및 그의 용도
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
DE60129154T2 (de) 2000-11-20 2008-02-28 Smithkline Beecham Corp. Neuartige verbindungen
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
JP4267920B2 (ja) 2001-01-26 2009-05-27 中外製薬株式会社 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
BR0308854A (pt) 2002-03-29 2005-02-22 Chiron Corp Benzazolas substituìdas e seus usos como inibidoras de quinase raf
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1546117A2 (en) 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
BR0314372A (pt) 2002-09-18 2005-07-19 Pfizer Prod Inc Compostos imidazol como inibidores do fator de crescimento tranformador (tgf)
CA2499429C (en) 2002-09-18 2010-09-21 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
BRPI0415210A (pt) 2003-10-08 2006-12-05 Irm Llc compostos e composições como inibidores de proteìna cinase
DE602004021838D1 (de) 2003-10-16 2009-08-13 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
EP1692113B1 (en) 2003-11-14 2017-09-27 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
EP1721905A4 (en) 2004-03-05 2009-11-18 Taisho Pharmaceutical Co Ltd thiazole
KR100749566B1 (ko) 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
SI2298768T1 (en) 2004-06-11 2013-01-31 Japan Tobacco Inc 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyridoS2,3-dCpyrimidine derivatives and related compounds for the treatment of cancer
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
JP2008511631A (ja) 2004-08-31 2008-04-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
JP2008516962A (ja) 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
JP2007246520A (ja) 2006-02-15 2007-09-27 Takeda Yuichiro Ｒａｇｅ阻害剤
EP2007393B1 (en) 2006-04-07 2013-08-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
ES2657635T3 (es) 2006-08-08 2018-03-06 Chugai Seiyaku Kabushiki Kaisha Derivado de pirimidina como inhibidor de PI3K y uso del mismo
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
DK2170848T3 (en) 2007-06-27 2015-01-05 Astrazeneca Ab Pyrazinonderivater and their use to treat lung diseases
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
NZ582349A (en) 2007-06-29 2012-06-29 Sunesis Pharmaceuticals Inc Heterocyclic compounds useful as raf kinase inhibitors
WO2009003998A2 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
US20100261723A1 (en) 2007-07-09 2010-10-14 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AR067585A1 (es) 2007-07-19 2009-10-14 Schering Corp Compuestos heterociclicos de amidas como inhibidores de la proteincinasa
WO2009032667A1 (en) 2007-08-29 2009-03-12 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
WO2009030952A2 (en) 2007-09-05 2009-03-12 Astrazeneca Ab Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
AU2009227013B2 (en) 2008-03-21 2013-01-10 Novartis Ag Novel heterocyclic compounds and uses therof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
PT2324008E (pt) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
EP2716643A1 (en) 2008-08-22 2014-04-09 Novartis AG Pyrrolopyrimidine compounds and their uses
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AU2009327357C1 (en) 2008-12-19 2017-02-02 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of ATR kinase
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
KR20120092586A (ko) 2009-09-04 2012-08-21 노파르티스 아게 증식성 질환의 치료에 유용한 비피리딘
WO2011059610A1 (en) 2009-11-10 2011-05-19 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds
WO2011081205A1 (ja) 2009-12-28 2011-07-07 一般社団法人ファルマＩｐ １，３，４－オキサジアゾール－２－カルボキサミド化合物
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
AU2011268906A1 (en) 2010-06-25 2013-01-31 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
WO2012027438A1 (en) 2010-08-26 2012-03-01 Glaxosmithkline Llc Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
CN101993415B (zh) 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
JP5941069B2 (ja) 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
US20140221374A1 (en) 2011-03-17 2014-08-07 Ruga Corporation Raf kinase inhibitors
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
AP2014007493A0 (en) 2011-09-01 2014-03-31 Irm Llc Compounds and compositions as C-KIT kinase inhibitors
EP2758379B1 (en) 2011-09-21 2016-10-19 Cellzome Limited Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases
CA2871270A1 (en) 2012-05-02 2013-11-07 Lupin Limited Substituted pyridine compounds as crac modulators
CA2871332A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
TW201414704A (zh) 2012-07-02 2014-04-16 Biogen Idec Inc 作爲ＲＯＲ－γ受體之反向促效劑之含聯芳化合物
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
DK2882440T3 (da) 2012-08-07 2019-05-06 Novartis Ag Farmaceutiske kombinationer, der omfatter en b-raf-inhibitor, en egfr-inhibitor og eventuelt en pi3k-alfa-inhibitor
PT2892535T (pt) 2012-09-04 2021-12-15 Novartis Ag Método de tratamento adjuvante do cancro
KR102215272B1 (ko) 2012-09-28 2021-02-15 이그니타, 인코포레이티드 비정형 단백질 키나제 c의 아자퀴나졸린 억제제
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
ES2676177T3 (es) 2012-12-20 2018-07-17 Novartis Ag Una combinación farmacéutica que comprende binimetinib
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UA118846C2 (uk) 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
CN105658646B (zh) 2013-11-01 2018-11-27 诺华股份有限公司 作为激酶抑制剂的氨基杂芳基苯甲酰胺
MX384721B (es) 2013-12-20 2025-03-14 Biomed Valley Discoveries Inc Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
WO2016038582A1 (en) 2014-09-12 2016-03-17 Novartis Ag Compounds and compositions as raf kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
ES2844211T3 (es) 2014-09-12 2021-07-21 Novartis Ag Compuestos y composiciones en calidad de inhibidores de quinasa
WO2016115376A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Of California Detection and treatment of double drug resistant melanomas
NZ735715A (en) 2015-04-15 2022-09-30 Beigene Ltd Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
EA201890272A1 (ru) 2015-07-10 2018-08-31 Генмаб А/С Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
CN108348513A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 用于治疗或预防癌症的ribociclib与达拉菲尼的组合
JP2018528952A (ja) 2015-08-28 2018-10-04 ノバルティス アーゲー Ｐｉ３ｋ阻害剤のアルペリシブおよびｃｄｋ４／６阻害剤のリボシクリブを含む医薬組合せ、ならびにがんの治療／予防におけるその使用
PL3463345T3 (pl) 2016-06-03 2023-02-06 Array Biopharma Inc. Kombinacje farmaceutyczne
WO2017212442A1 (en) 2016-06-10 2017-12-14 Novartis Ag Therapeutic uses of a c-raf inhibitor
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
US11590133B2 (en) 2016-12-11 2023-02-28 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of BRAF mutant cancers
KR20240032157A (ko) * 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
WO2018213302A1 (en) 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
TWI827550B (zh) 2017-09-08 2024-01-01 美商建南德克公司 癌症之診斷及治療方法
WO2020046966A1 (en) 2018-08-27 2020-03-05 Kura Oncology, Inc. Treatment of adenocarcinomas with mapk pathway inhibitors
JP2022514056A (ja) 2018-12-20 2022-02-09 ノバルティス アーゲー 癌の治療に使用するためのＲａｆ阻害剤及びＣＤＫ４／６阻害剤による組み合わせ療法
CN113795490A (zh) 2019-05-13 2021-12-14 诺华股份有限公司 N-(3-(2-(2-羟基乙氧基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-2(三氟甲基)异烟酰胺的新结晶形式作为Raf抑制剂治疗癌症
EP4106756A1 (en) 2020-02-18 2022-12-28 Novartis AG Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
EP4149472A1 (en) 2020-05-12 2023-03-22 Novartis AG Therapeutic combinations comprising a craf inhibitor
TW202227088A (zh) 2020-08-31 2022-07-16 瑞士商諾華公司 組合療法

Also Published As

Publication number Publication date
RU2019134757A3 (es) 2021-08-17
US12036227B2 (en) 2024-07-16
IL270224B1 (en) 2024-04-01
EP3618875B1 (en) 2023-04-05
JP7520189B2 (ja) 2024-07-22
ES2952265T3 (es) 2023-10-30
FI3618875T3 (fi) 2023-07-04
AU2018262891B2 (en) 2021-04-01
MX393855B (es) 2025-03-21
PT3618875T (pt) 2023-08-07
CA3057969A1 (en) 2018-11-08
CN110494166A (zh) 2019-11-22
JP7309614B2 (ja) 2023-07-18
JP2024160223A (ja) 2024-11-13
JP2020518568A (ja) 2020-06-25
CN110494166B (zh) 2022-11-08
BR112019022511A2 (pt) 2020-05-12
AU2018262891A1 (en) 2019-10-17
EP3618875A1 (en) 2020-03-11
DK3618875T3 (da) 2023-07-10
US11266653B2 (en) 2022-03-08
IL311471A (en) 2024-05-01
CL2019003091A1 (es) 2020-02-07
KR20240032157A (ko) 2024-03-08
TW201842914A (zh) 2018-12-16
KR20190141164A (ko) 2019-12-23
WO2018203219A1 (en) 2018-11-08
JP2023145467A (ja) 2023-10-11
US20220143036A1 (en) 2022-05-12
IL270224A (es) 2019-12-31
RU2019134757A (ru) 2021-06-02
US20200246346A1 (en) 2020-08-06
TWI798218B (zh) 2023-04-11
EP4272740A1 (en) 2023-11-08
KR102641827B1 (ko) 2024-03-04
PL3618875T3 (pl) 2023-10-23

Similar Documents

Publication Publication Date Title
MX2019012884A (es) Terapia de combinacion.
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
MX2019009443A (es) Metodos para tratar la influenza.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
EA033298B1 (ru) Комбинированная лекарственная форма тезофензина и метопролола
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor